Auris Medical Holding (EARS) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Auris Medical Provides Business Update and Reports Third Quarter 2016 Financial Results
November 10, 2016 6:30 AM ESTAM-111 Phase 3 program for acute inner ear hearing loss is ongoing Amended TACTT3 trial of KeyzilenTM provides clear path forward for acute inner ear tinnitus program Conference call today at 8 am Eastern Time
ZUG, Switzerland, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the third quarter ended Sept. 30, 2016.
... More